Inhibition of lung tumor growth in nude mice by siRNACD31 targeting PECAM‑1

Ouyang,Jin‑Sheng; Li,Yu‑Ping; Chen,Cheng‑Shui; Chen,Jun‑Jie; Chen,Tong‑Ke; Cai,Chang; Yang,Li

doi:10.3892/ol.2014.2091

Inhibition of lung tumor growth in nude mice by siRNACD31 targeting PECAM‑1

Authors:
- Jin‑Sheng Ouyang
- Yu‑Ping Li
- Cheng‑Shui Chen
- Jun‑Jie Chen
- Tong‑Ke Chen
- Chang Cai
- Li Yang
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 32500, P.R. China
Published online on: April 25, 2014 https://doi.org/10.3892/ol.2014.2091
Pages: 33-40

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small interfering RNA (siRNA) provides a promising therapeutic approach in the silencing of disease‑causing genes. In the present study, the use of 2'‑O‑methyl‑modified siRNA‑cluster of differentiation 31 (siRNACD31), with cationic liposome RNA interference (RNAi)‑mate as a carrier, effectively silenced the platelet endothelial cell molecule 1 (PECAM‑1) gene of murine hemangioendothelioma cells in vitro. In vivo, 2'‑O‑methyl‑modified siRNACD31 carried by RNAi‑mate was successfully delivered, targeting the PECAM‑1 gene in the vasculature of nude mouse lung carcinoma xenografts. The growth of the lung carcinoma xenografts was inhibited by the 2'‑O‑methyl‑modified siRNACD31 and RNAi‑mate complexes, and the expression of the PECAM‑1 protein was downregulated, with a simultaneous decrease in vascular endothelial growth factor (VEGF) protein in the lung carcinoma xenografts. 2'‑O‑methyl‑modified siRNACD31‑RNAi‑mate complexes may provide a potential therapeutic strategy in lung carcinoma treatment. The effect of PECAM‑1 on VEGF expression may possibly be attributed to the function of PECAM‑1 signal transduction.

View Figures

View References

1	Kim ST, Uhm JE, Lee J, et al: Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer. 75:82–88. 2012.
2	Cohen MH, Williams GA, Sridhara R, Chen G and Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 8:303–306. 2003.
3	Perez-Soler R: The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res. 10:4238s–4240s. 2004.
4	de Gramont A and Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology. 69(Suppl 3): 46–56. 2005.
5	Park S, DiMaio TA, Scheef EA, Sorenson CM and Sheibani N: PECAM-1 regulates proangiogenic properties of endothelial cells through modulation of cell-cell and cell-matrix interactions. Am J Physiol Cell Physiol. 299:C1468–C1484. 2010.
6	Woodfin A, Voisin MB and Nourshargh S: PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol. 27:2514–2523. 2007.
7	Bautch VL: VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harb Perspect Med. 2:a0064522012.
8	Yang L, Guan H, He J, Zeng L, Yuan Z, Xu M, Zhang W, Wu X and Guan J: VEGF increases the proliferative capacity and eNOS/NO levels of endothelial progenitor cells through the calcineurin/NFAT signalling pathway. Cell Biol Int. 36:21–27. 2012.
9	Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 99:11393–11398. 2002.
10	Ilan N and Madri JA: PECAM-1: old friend, new partners. Curr Opin Cell Biol. 15:515–524. 2003.
11	Watt SM, Gschmeissner SE and Bates PA: PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Leuk Lymphoma. 17:229–244. 1995.
12	Müller AM, Hermanns MI, Skrzynski C, Nesslinger M, Müller KM and Kirkpatrick CJ: Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. Exp Mol Pathol. 72:221–229. 2002.
13	DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA and Albelda SM: Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 151:671–677. 1997.
14	Zhou Z, Christofidou-Solomidou M, Garlanda C and DeLisser HM: Antibody against murine PECAM-1 inhibits tumor angiogenesis in mice. Angiogenesis. 3:181–188. 1999.
15	Tachezy M, Reichelt U, Melenberg T, Gebauer F, Izbicki JR and Kaifi JT: Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Histol Histopathol. 25:1239–1246. 2010.
16	Herbst RS, Ansari R, Bustin F, et al: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 377:1846–1854. 2011.
17	Prager GW, Lackner EM, Krauth MT, et al: Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol. 4:150–160. 2010.
18	Inai T, Mancuso M, Hashizume H, et al: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 165:35–52. 2004.
19	Lagnien-Gaume V, Jehl J, Manzoni P, et al: Bevacizumab and lung cancer: eligible patients in daily practice. Rev Mal Respir. 28:25–31. 2011.(In French).
20	Soutschek J, Akinc A, Bramlage B, et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 432:173–178. 2004.
21	Chien PY, Wang J, Carbonaro D, et al: Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 12:321–328. 2005.
22	Aleku M, Schulz P, Keil O, et al: Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68:9788–9798. 2008.
23	Czauderna F, Fechtner M, Dames S, et al: Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31:2705–2716. 2003.
24	Ouyang JS, Li YP, Li CY, et al: Mitochondrial ROS-K+ channel signaling pathway regulated secretion of human pulmonary artery endothelial cells. Free Radic Res. 46:1437–1445. 2012.
25	Bidwell GL III, Perkins E and Raucher D: A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett. 319:136–143. 2012.
26	Feng D, Nagy JA, Pyne K, Dvorak HF and Dvorak AM: Ultrastructural localization of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endothelium. J Histochem Cytochem. 52:87–101. 2004.
27	Dimaio TA, Wang S, Huang Q, Scheef EA, Sorenson CM and Sheibani N: Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice. Dev Biol. 315:72–88. 2008.
28	DeLisser H, Liu Y, Desprez PY, et al: Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc Natl Acad Sci USA. 107:18616–18621. 2010.
29	Delisser HM: Targeting PECAM-1 for anti-cancer therapy. Cancer Biol Ther. 6:121–122. 2007.
30	Aleku M, Fisch G, Möpert K, Keil O, Arnold W, Kaufmann J and Santel A: Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues. Microvasc Res. 76:31–41. 2008.
31	Newman PJ and Newman DK: Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol. 23:953–964. 2003.
32	Ilan N, Mahooti S, Rimm DL and Madri JA: PECAM-1 (CD31) functions as a reservoir for and a modulator of tyrosine-phosphorylated beta-catenin. J Cell Sci. 112:3005–3014. 1999.
33	Wang Y and Sheibani N: PECAM-1 isoform-specific activation of MAPK/ERKs and small GTPases: implications in inflammation and angiogenesis. J Cell Biochem. 98:451–468. 2006.
34	Masuda M, Kogata N and Mochizuki N: Crucial roles of PECAM-1 in shear stress sensing of vascular endothelial cells. Nihon Yakurigaku Zasshi. 124:311–318. 2004.(In Japanese).
35	Fujiwara K, Masuda M, Osawa M, Kano Y and Katoh K: Is PECAM-1 a mechanoresponsive molecule? Cell Struct Funct. 26:11–17. 2001.
36	Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA and Gamble JR: Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood. 105:3169–3177. 2005.
37	Bergom C, Goel R, Paddock C, Gao C, Newman DK, Matsuyama S and Newman PJ: The cell-adhesion and signaling molecule PECAM-1 is a molecular mediator of resistance to genotoxic chemotherapy. Cancer Biol Ther. 5:1699–1707. 2006.
38	Wu N, Kurosu T, Oshikawa G, Nagao T and Miura O: PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. Int J Oncol. 42:419–428. 2013.
39	Masuda M, Osawa M, Shigematsu H, Harada N and Fujiwara K: Platelet endothelial cell adhesion molecule-1 is a major SH-PTP2 binding protein in vascular endothelial cells. FEBS Lett. 408:331–336. 1997.
40	Enciso JM, Gratzinger D, Camenisch TD, Canosa S, Pinter E and Madri JA: Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2. J Cell Biol. 160:605–615. 2003.
41	Privratsky JR, Tilkens SB, Newman DK and Newman PJ: PECAM-1 dampens cytokine levels during LPS-induced endotoxemia by regulating leukocyte trafficking. Life Sci. 90:177–184. 2012.